Clinical Trial Phases - NAPLEX

1. A monoclonal antibody for psoriasis has been on the market for three years. The FDA now requires the manufacturer to conduct a study to evaluate the long-term risk of developing lymphoma in patients taking the medication. This regulatory requirement is an example of which type of clinical study?
   Answer: A Phase 4 trial, also known as a post-marketing surveillance study. When you encounter questions about studies conducted after a drug is already on the market, you're dealing with post-marketing surveillance requirements. The FDA often mandates these studies when new safety concerns emerge or when long-term effects need monitoring in real-world populations. This scenario describes a classic Phase 4 study. The monoclonal antibody has been marketed for three years, and the FDA now requires investigation of long-term lymphoma risk. Phase 4 trials, also called post-marketing surveillance studies, specifically monitor drugs after approval to identify rare or delayed adverse effects that weren't detected in pre-approval trials. These studies often involve larger populations over longer periods than the original clinical trials. Option A is incorrect because Phase 1 trials focus on determining maximum tolerated dose and basic safety in small groups of participants, typically during initial drug development—not years after market approval. Option B misses the mark because Phase 2 trials explore efficacy for new indications, but this study isn't testing the drug for a different condition; it's monitoring safety in the current indication. Option C is wrong because Phase 3 trials are large-scale efficacy studies conducted before initial approval or for specific population expansions, but the question describes ongoing safety monitoring, not seeking new approval. For NAPLEX success, remember that Phase 4 studies are the only clinical trial phase that occurs after market approval. When you see "post-marketing," "long-term safety monitoring," or "FDA requires manufacturer to study" in the context of an already-approved drug, think Phase 4.
2. A 62-year-old male (90 kg) with hypertension (baseline blood pressure 156/92 mmHg, serum potassium 4.2 mEq/L, serum creatinine 1.0 mg/dL) is screened for a Phase III trial of pressoril, a new once-daily antihypertensive, compared with lisinopril. The trial is multicenter, randomized, double-blind, and powered to compare pressoril versus standard therapy on mean systolic blood pressure reduction and rates of common adverse events over 24 weeks; all participants provide informed consent before randomization. What distinguishes this Phase III trial from other phases?
   Answer: It is designed to confirm efficacy and monitor safety in a large population compared with standard therapy This question tests understanding of Phase III clinical trials, which are pivotal studies designed to confirm efficacy and safety before regulatory approval. Phase III trials are distinguished by their large sample size, comparison to standard therapy, and focus on clinically meaningful endpoints to support regulatory approval. Option B correctly identifies these distinguishing features: confirming efficacy and monitoring safety in a large population compared with standard therapy. Option A incorrectly describes Phase I trials with first-in-human safety focus. Option C describes Phase IV post-marketing surveillance. Option D is incorrect because all clinical trial phases require informed consent regardless of whether the medication is used in practice. The clinical pearl is that Phase III trials are "registration trials" that provide definitive evidence of efficacy and safety compared to existing treatments, using rigorous randomized controlled trial designs to minimize bias.
3. A 56-year-old woman (72 kg) with major depressive disorder enrolls in a Phase II trial of SERENEX, a new oral antidepressant. The study evaluates two doses versus placebo for 8 weeks; the primary endpoint is change in a validated depression rating scale, and common adverse effects (nausea, insomnia) are tracked. She signs informed consent and is informed about the use of placebo and rescue options for worsening symptoms. Which outcome is most important for this Phase II study?
   Answer: Change in depression rating scale score to assess preliminary efficacy and inform dose selection This question assesses Phase II outcomes for antidepressants. Phase II focuses on preliminary efficacy like rating scale changes for dose selection. Choice A is the best answer as it informs development. Choice B is Phase III; choice C is Phase IV; and choice D is Phase I. Misconceptions include comparative focus in Phase II. Ethical placebo and rescue options are crucial. A pearl is using Phase II to ethically advance promising therapies.
4. A 33-year-old woman (59 kg) is a healthy volunteer in a Phase I trial of HEPATO-GUARD, a new oral agent intended to treat nonalcoholic fatty liver disease in future studies. The protocol evaluates single ascending doses with monitoring of adverse events and liver tests; baseline AST is 16 U/L and ALT is 19 U/L. She signs informed consent after discussion of risks, compensation, and confidentiality. What is the primary goal of this Phase I clinical trial?
   Answer: Determine safety/tolerability and characterize pharmacokinetics to support dose selection for later trials This question examines Phase I goals for liver disease agents. Phase I determines safety and pharmacokinetics to support dosing. Choice A is the best answer because it guides later trials. Choice B is Phase III; choice C is Phase IV; and choice D is also Phase III. A misconception is patient efficacy in Phase I. Consent details risks. A framework is phased safety to efficacy progression.
5. A 28-year-old woman (62 kg) with uncomplicated mild hypertension is enrolled in a first-in-human study of NOVA-101, an oral vasodilator with a new mechanism of action. The protocol is a Phase I dose-escalation trial in healthy volunteers to determine tolerability and characterize pharmacokinetics; blood pressure, heart rate, and liver enzymes (AST/ALT) are monitored after single and multiple doses. She signs written informed consent after risks, alternatives, and compensation are explained. What is the primary goal of this Phase I clinical trial?
   Answer: Determine safety, tolerability, and an appropriate dosing range while describing pharmacokinetics This question tests the understanding of Phase I clinical trials in drug development. The critical objective of Phase I is to evaluate initial safety, tolerability, pharmacokinetics, and dosing in a small group of healthy volunteers or patients. Choice B is the best answer because it directly aligns with the primary goals of Phase I, focusing on safety and pharmacokinetic data to inform subsequent phases. Choice A is incorrect as it describes a Phase III objective of demonstrating superiority in efficacy; choice C reflects Phase IV post-marketing surveillance for rare events; and choice D pertains to Phase III confirmation of efficacy in larger patient groups. A common misconception is confusing Phase I with later phases that assess efficacy, but Phase I prioritizes safety over therapeutic benefit. A key clinical pearl is that ethical considerations in Phase I emphasize voluntary informed consent and the right to withdraw, ensuring participant autonomy. Understanding trial phases helps pharmacists guide patients on investigational drugs, balancing potential risks with the stepwise progression of evidence.
6. A 40-year-old man (81 kg) with mild plaque psoriasis enrolls in a Phase II trial of PLAQUENIL-NEW, a topical immunomodulator (new formulation) intended to reduce plaque severity. The study evaluates two strengths for 12 weeks; primary endpoint is proportion achieving a clinically meaningful improvement in a psoriasis severity score, and local irritation is tracked. He signs informed consent and is told the product is investigational and may not work. Which outcome is most important for this Phase II study?
   Answer: Proportion achieving clinically meaningful improvement in psoriasis severity to assess preliminary efficacy and dose selection This question evaluates Phase II outcomes for dermatologic agents. Phase II prioritizes efficacy like severity improvement for dose selection. Choice A is the best answer as it assesses preliminary signals. Choice B is Phase IV; choice C is Phase III; and choice D is Phase I. Misconceptions expect definitive or rare data in Phase II. Ethical investigational status disclosure is vital. A pearl is Phase II's bridge to confirmatory trials, ethically balancing innovation and safety.
7. A 60-year-old man (95 kg) with hyperlipidemia is enrolled in a Phase II trial of LIPIDRA, an oral agent designed to lower low-density lipoprotein cholesterol (LDL-C). The trial tests two dose levels versus placebo for 8 weeks in patients with LDL-C >160 mg/dL; baseline LDL-C is 192 mg/dL and alanine aminotransferase (ALT) is 22 U/L. He signs informed consent after being told about potential liver enzyme elevations and myalgias. Which patient characteristic is crucial for this trial phase?
   Answer: Having the target disease/condition (elevated LDL-C) to allow assessment of preliminary efficacy and dose response This question examines key participant characteristics for Phase II clinical trials. The crucial characteristic is enrolling patients with the target condition to evaluate preliminary efficacy and dose response in the intended population. Choice A is the best answer as it directly relates to assessing drug effects in diseased patients, unlike healthy volunteers in Phase I. Choice B describes Phase I participants; choice C is for Phase IV surveillance; and choice D is irrelevant to Phase II design. Misconceptions often confuse Phase II with healthy volunteer studies, but it shifts to patients for efficacy signals. Ethically, informed consent in Phase II must detail potential benefits and risks specific to the disease state. A transferable pearl is that trial phases build evidence hierarchically, with Phase II bridging safety data to large-scale efficacy confirmation.
8. A 71-year-old man (80 kg) is taking GLUCOFIX, a newly marketed oral diabetes medication, and is enrolled in a Phase IV safety study. The study uses insurance claims and periodic lab data to evaluate rates of pancreatitis and severe hypoglycemia over 5 years; baseline A1C is 7.4%. He signs informed consent and is told his data will be de-identified for analysis. Which factor is critical in this Phase IV trial?
   Answer: Long-term and rare adverse event monitoring in real-world use after the drug is approved This question identifies critical aspects of Phase IV studies in diabetes management. Phase IV is crucial for long-term safety monitoring and rare events post-approval. Choice A is the best answer because it focuses on real-world data collection. Choice B is Phase I; choice C is Phase II; and choice D wrongly eliminates consent. A misconception is Phase IV lacking rigor, but it requires ethics. Informed consent protects privacy in data use. A framework is post-approval vigilance to refine drug utilization safely.
9. A physician wishes to prescribe an investigational drug for a patient with a life-threatening condition who is not eligible for any ongoing clinical trials. The drug has completed Phase 2 testing but is not yet approved. Which pathway would allow the manufacturer to provide this drug to the patient outside of a formal clinical trial?
   Answer: A Right to Try request or Expanded Access Program When you encounter questions about accessing unapproved medications for patients with serious conditions, focus on the regulatory pathways designed specifically for compassionate use situations. The correct answer is D because both Right to Try laws and FDA Expanded Access Programs are specifically designed to provide investigational drugs to patients with serious or life-threatening conditions who cannot participate in clinical trials. Since this drug has completed Phase 2 testing, it meets the eligibility criteria for these pathways. Right to Try is a federal law allowing access to investigational drugs that have completed Phase 1 testing, while Expanded Access (also called "compassionate use") is an FDA program that serves the same purpose but requires FDA approval. Answer A is incorrect because an ANDA is used to seek approval for generic versions of already-approved brand-name drugs, not for providing investigational medications. Answer B is wrong because Phase 4 post-marketing commitments are studies required after a drug is already approved and marketed to monitor long-term safety or efficacy—this doesn't apply to unapproved drugs. Answer C is incorrect because MedWatch is the FDA's safety information and adverse event reporting system, not a pathway for accessing investigational drugs. Remember that compassionate use pathways are specifically created for situations where standard treatment options are exhausted and patients cannot access clinical trials. When you see scenarios involving investigational drugs for desperate patients, think "compassionate use" and look for Right to Try or Expanded Access in the answer choices.
10. A 44-year-old man (92 kg) with gastroesophageal reflux disease enrolls in a Phase II trial of ACIDOFF, a new oral acid-suppressing medication. The study evaluates two doses versus placebo for 6 weeks; the primary endpoint is proportion of patients with symptom-free days, and safety endpoints include serum magnesium (baseline 2.0 mg/dL). He signs informed consent after discussion of potential diarrhea and headache. Which outcome is most important for this Phase II study?
    Answer: Proportion of symptom-free days to assess preliminary efficacy and inform dose selection This question assesses key outcomes in Phase II trials for gastrointestinal drugs. The primary outcome for Phase II is preliminary efficacy indicators like symptom-free days to inform dosing and progression. Choice A is the best answer as it focuses on dose-response and efficacy signals in patients. Choice B is Phase III comparison; choice C is Phase IV rare events; and choice D is Phase I dosing. Misconceptions include Phase II providing definitive comparisons, reserved for Phase III. Ethical consent must cover placebo and side effects. A clinical pearl is evaluating surrogate endpoints in Phase II to predict clinical benefits ethically.
11. A 58-year-old female (72 kg) with moderate chronic obstructive pulmonary disease (forced expiratory volume in 1 second 55% predicted) is approached for a Phase II trial of bronchexa, an investigational inhaled bronchodilator, versus placebo for 16 weeks. The study seeks to evaluate preliminary efficacy and dose response while monitoring common adverse effects; endpoints include change in forced expiratory volume in 1 second and rescue inhaler use. She is asked to sign informed consent and confirm she can comply with scheduled visits and spirometry testing. Which patient characteristic is crucial for this trial phase?
    Answer: Ability to adhere to protocol visits and procedures to reliably assess efficacy and side effects This question tests understanding of patient characteristics important for Phase II clinical trials. Phase II trials require patients with the target disease who can reliably complete protocol requirements to generate valid efficacy and safety data. Option A correctly identifies the crucial characteristic: ability to adhere to protocol visits and procedures to reliably assess efficacy and side effects. Option B incorrectly requires prior drug exposure, which would exclude treatment-naive patients. Option C incorrectly limits enrollment to healthy volunteers, which is typical of Phase I but not Phase II where efficacy in the target population is assessed. Option D incorrectly requires commercial availability, which only occurs after Phase III completion and regulatory approval. The clinical principle is that Phase II trials balance the need for homogeneous populations to detect efficacy signals with practical considerations of patient adherence and protocol feasibility.
12. A new oral anticoagulant has successfully completed a trial involving 250 patients with atrial fibrillation. The trial demonstrated a dose-dependent effect on a surrogate endpoint and identified the optimal dose for further study. The most common adverse effects were minor bleeding and dyspepsia. What is the primary objective of the next phase of clinical development for this drug?
    Answer: To confirm safety and efficacy in a large, diverse patient population compared to the standard of care. Clinical drug development follows a well-defined sequence of phases, each with specific objectives. When you see questions about clinical trials, focus on matching the study characteristics to the appropriate phase goals. This scenario describes a completed Phase II trial: 250 patients (moderate size), dose-finding study, surrogate endpoint evaluation, and safety profiling. The next logical step is Phase III, which has the primary objective of confirming safety and efficacy in large, diverse patient populations using clinically meaningful endpoints compared to standard treatments. Choice C is correct because Phase III trials are designed to provide definitive evidence of therapeutic benefit in thousands of patients across multiple centers, comparing the new drug to existing standard-of-care treatments. This phase generates the pivotal data needed for regulatory approval. Choice A describes Phase I objectives, which occur much earlier in development with healthy volunteers or small patient groups to establish basic safety, dosing, and pharmacokinetics. This phase has already been completed for this drug. Choice B is premature because surrogate endpoints from a 250-patient trial don't provide sufficient evidence for NDA filing. The FDA requires robust Phase III data demonstrating clinical benefit, not just surrogate marker effects. Choice D describes Phase IV (post-marketing surveillance), which only occurs after FDA approval when the drug is commercially available. You can't conduct post-marketing studies on an unapproved drug. Remember: Phase II identifies the dose and shows promise; Phase III proves it works in real-world populations. Always match the trial description to the sequential phase objectives when answering drug development questions.
13. A 22-year-old man (75 kg) is a healthy volunteer in a Phase I trial of SEDATOL, a new oral anxiolytic. The trial uses ascending doses and measures sedation scores, respiratory rate, and plasma concentrations; baseline creatinine is 0.8 mg/dL. He signs informed consent after being told not to drive and that he can stop participation at any time. What is the primary goal of this Phase I clinical trial?
    Answer: Determine safety/tolerability and characterize pharmacokinetics to guide dosing for later studies This question examines the main goals of Phase I trials for CNS agents. Phase I primarily determines safety, tolerability, and pharmacokinetics to guide future dosing. Choice A is the best answer because it emphasizes foundational data in healthy volunteers. Choice B is Phase III confirmation; choice C is Phase IV evaluation; and choice D overstates efficacy focus. A misconception is Phase I focusing on efficacy, but it's safety-oriented. Ethically, highlight no-driving rules and withdrawal rights. A decision framework prioritizes phased objectives: safety first, then layered efficacy assessments.
14. A 52-year-old male (88 kg) with osteoarthritis begins taking arthriquel, a newly approved oral anti-inflammatory agent. He is enrolled in a Phase IV observational study that uses electronic health record follow-up to assess real-world rates of gastrointestinal bleeding and renal events over 2 years; baseline serum creatinine is 0.9 mg/dL and hemoglobin is 15.0 g/dL. The research team obtains informed consent for data collection and explains privacy protections and the ability to withdraw authorization. What ethical consideration is central to this trial phase?
    Answer: Ensuring ongoing informed consent and protecting confidentiality during long-term real-world data collection This question tests understanding of ethical considerations specific to Phase IV observational studies. Phase IV studies using real-world data require ongoing attention to informed consent and data privacy, even though the drug is already approved and prescribed. Option B correctly identifies the central ethical consideration: ensuring ongoing informed consent and protecting confidentiality during long-term real-world data collection. Option A is incorrect because approved status doesn't eliminate consent requirements for research. Option C is incorrect because safety reporting to regulators is mandatory, not optional. Option D incorrectly restricts to healthy volunteers, which would defeat the purpose of real-world effectiveness studies. The ethical principle is that Phase IV studies, while observational, still constitute research requiring consent, especially when collecting identifiable health information over extended periods, with particular attention to data security and participant autonomy.
15. A 29-year-old man (78 kg) is a healthy volunteer in a Phase I trial of IMMUN-9, an oral agent intended to reduce inflammation in autoimmune disease. The trial includes dose escalation with monitoring for adverse events, complete blood count (baseline absolute neutrophil count 3.2 $x10^3$/µL), and liver enzymes. He signs informed consent after the study team explains risks, confidentiality, and that the drug may not benefit him. What is the primary goal of this Phase I clinical trial?
    Answer: Determine safety and tolerability and identify a dosing range appropriate for later patient studies This question tests Phase I objectives for immunomodulators. Phase I aims to establish safety, tolerability, and dosing for later studies. Choice B is the best answer because it focuses on preparatory data. Choice A is Phase III; choice C is Phase IV; and choice D is not primary. A misconception is efficacy in Phase I, but it's safety. Consent explains no direct benefit. A framework is ethical staging: safety before efficacy.
16. A pharmaceutical company is developing a novel kinase inhibitor for the treatment of non-small cell lung cancer. The initial human trial enrolls 45 patients with treatment-refractory disease. The study design involves escalating doses to identify the highest dose that can be administered without unacceptable toxicity. Which clinical trial phase does this study best represent?
    Answer: Phase 1, as it is primarily designed to assess safety and determine the maximum tolerated dose in patients. When you encounter clinical trial questions on the NAPLEX, focus on the primary objective of each phase rather than getting distracted by secondary characteristics like patient population or sample size. This study's primary goal is dose escalation to find the "highest dose that can be administered without unacceptable toxicity" — this is the classic definition of determining maximum tolerated dose (MTD), which is the hallmark of Phase 1 trials. Phase 1 studies prioritize safety assessment and dose-finding in humans, typically using escalating dose protocols exactly as described here. The fact that these are cancer patients doesn't change the phase classification since oncology trials often use patients rather than healthy volunteers for ethical reasons. Choice A is incorrect because Phase 0 trials use subtherapeutic microdoses specifically to study pharmacokinetics without therapeutic effect — this study uses escalating therapeutic doses. Choice C misidentifies this as Phase 2, but while Phase 2 trials do enroll patients with the target disease, their primary endpoint is preliminary efficacy assessment, not dose-finding. The question gives no indication that efficacy is being measured. Choice D incorrectly suggests Phase 3 characteristics, but Phase 3 trials are large-scale comparative effectiveness studies against standard treatments, not dose-escalation safety studies. Key strategy: Remember that clinical trial phases are defined by their primary objective, not their patient population. Phase 1 = safety and dose-finding, Phase 2 = preliminary efficacy, Phase 3 = comparative effectiveness. The mention of "escalating doses" and "maximum tolerated dose" should immediately point you toward Phase 1.
17. A pharmaceutical company is conducting a first-in-human study for a new CNS agent. The study enrolls 10 healthy volunteers and administers a single dose that is 1/100th of the dose that produced a therapeutic effect in animal models. The goal is to collect preliminary human pharmacokinetic data using highly sensitive analytical methods. This type of study is best classified as:
    Answer: Phase 0 When you encounter questions about clinical trial phases, focus on the key characteristics that distinguish each phase: population size, dose levels, and primary objectives. This study has the hallmarks of a Phase 0 trial. Phase 0 studies use microdoses (typically 1/100th or less of the therapeutic dose), enroll very small populations (usually under 15 participants), and focus solely on gathering preliminary pharmacokinetic data using highly sensitive analytical methods. The goal isn't to test efficacy or even safety in a traditional sense, but to understand how the human body processes the drug at sub-therapeutic levels. Looking at the wrong answers: Option B (Phase 1) is tempting since both phases use healthy volunteers, but Phase 1 studies use therapeutic doses, enroll larger groups (20-100 participants), and focus on determining maximum tolerated dose and dose-limiting toxicities. Option C (Phase 2a) involves patients with the target condition, not healthy volunteers, and tests preliminary efficacy at therapeutic doses. Option D (Preclinical) refers to laboratory and animal studies that occur before any human testing begins. The correct answer is A (Phase 0). For NAPLEX success, remember that Phase 0 trials are relatively new additions to drug development and are characterized by three key features: microdosing (sub-therapeutic levels), very small study populations, and pharmacokinetic objectives only. If you see "1/100th therapeutic dose" combined with "preliminary PK data," think Phase 0 immediately.
18. A 33-year-old male (76 kg) with mild hyperlipidemia (low-density lipoprotein cholesterol 148 mg/dL, alanine aminotransferase 24 U/L) is invited to participate in a Phase I trial of lipidoran, a new oral lipid-lowering agent, involving intensive blood sampling for pharmacokinetics and frequent safety labs. The study team explains foreseeable risks, potential benefits, alternatives, confidentiality, compensation for injury, and that participation is voluntary with the right to withdraw at any time before the patient signs consent. What ethical consideration is central to this trial phase?
    Answer: Obtaining valid informed consent before any study-specific procedures and minimizing risk through monitoring This question tests understanding of ethical considerations in Phase I clinical trials, particularly the importance of informed consent. The central ethical consideration in Phase I trials is obtaining valid informed consent before any study procedures, given that these first-in-human studies carry unknown risks with minimal direct benefit to participants. Option B correctly identifies this requirement: obtaining valid informed consent before study procedures and minimizing risk through monitoring. Option A is incorrect because informed consent cannot be waived regardless of endpoints. Option C describes Phase IV post-marketing surveillance, not Phase I ethics. Option D incorrectly suggests Phase III superiority is required before Phase I, which reverses the proper sequence. The ethical principle is that Phase I participants, often healthy volunteers, assume risk primarily for societal benefit, making comprehensive informed consent and risk minimization through careful monitoring essential ethical obligations.
19. A 52-year-old woman (74 kg) with osteoarthritis knee pain is invited to join a Phase III trial of PAINLESS-X, a new oral non-opioid analgesic. The study randomizes participants to PAINLESS-X or naproxen for 12 weeks; primary endpoint is change in a validated pain score, and safety endpoints include gastrointestinal bleeding and serum creatinine (baseline 0.9 mg/dL). She signs informed consent and is told about randomization and the possibility of receiving either treatment. What distinguishes this Phase III trial from other phases?
    Answer: It confirms efficacy and safety by comparing the investigational drug to standard therapy in a large patient population This question assesses the unique aspects of Phase III clinical trials in drug development. The distinguishing feature of Phase III is its large-scale confirmation of efficacy and safety, often comparing to standard therapy in patients. Choice B is the best answer because it emphasizes the confirmatory, comparative design pivotal for approval. Choice A is Phase I; choice C is Phase IV; and choice D is preclinical or in vitro work. A misconception is viewing Phase III as exploratory like Phase II, but it provides definitive evidence. Clinically, ethical considerations include equitable randomization and monitoring to balance risks. A framework for phases is to consider objectives: safety-first (I), efficacy exploration (II), confirmation (III), and real-world (IV).
20. A 63-year-old man (88 kg) with heart failure with reduced ejection fraction is screened for a Phase III trial of INOTRA, an oral agent intended to improve exercise tolerance. The multicenter study randomizes patients to INOTRA plus standard therapy versus placebo plus standard therapy for 18 months; primary endpoint is time to cardiovascular death or heart failure hospitalization. He signs informed consent after being told about potential risks, including hypotension and arrhythmias. What distinguishes this Phase III trial from other phases?
    Answer: It confirms efficacy and safety in a large patient population using clinically meaningful endpoints This question distinguishes Phase III clinical trials in cardiovascular drug development. Phase III is characterized by large-scale randomized comparisons to confirm efficacy and safety against standards or placebo. Choice B is the best answer as it captures the confirmatory scale and clinical endpoints for approval. Choice A is Phase I; choice C is Phase IV; and choice D is not a clinical phase. Misconceptions confuse Phase III with post-marketing, but it precedes approval. Ethical emphasis is on informed consent for long-term risks like arrhythmias. A pearl is that Phase III data form the basis for labeling, guiding pharmacist counseling on evidence-based use.

Start this quiz